Skip to main content

Advertisement

SpringerLink
Log in

Somatic variation and cancer: therapies lost in the mix

  • Review Paper
  • Published:
Human Genetics Aims and scope Submit manuscript

Abstract

Cancer arises as a consequence of mutations in genomes of cancer cells, which over time allow them to proliferate and spread to distant sites. Large-scale sequencing of cancer genomes is revealing an increasing number of potential driver mutations that may allow specific targeting of cancer genes, proteins, and pathways. Comprehensive views of cancer genomes are also revealing enormous heterogeneity of mutation profiles, even among tumours derived from the same organs and having similar pathological characteristics. There are now many examples where mutation profiles observed in tumours have been shown to correlate with clinical features of disease, drug response, and patient outcomes. When ignored, molecular heterogeneity can lead to failures in drug development, as drugs that may have efficacy in subgroups of patients with specific molecular phenotypes may show marginal response when tested in large groups of unselected patients. This article explores issues relevant to the clinical translation of sequence-based mutation profiles in the clinical development of targeted therapies and in the future management of cancer patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • (2011a) Cancer drugs: remedy required. Nat Med 17:231

  • (2011b) Regulatory watch: FDA guidance on co-developing investigational drugs. Nat Rev Drug Discov 10:86. http://www.nature.com/nrd/journal/v10/n2/index.html

  • Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091–2096

    Article  PubMed  Google Scholar 

  • Andre F, McShane LM, Michiels S, Ransohoff DF, Altman DG, Reis-Filho JS, Hayes DF, Pusztai L (2011) Biomarker studies: a call for a comprehensive biomarker study registry. Nat Rev Clin Oncol 8:171–176

    Article  PubMed  Google Scholar 

  • Arrowsmith J (2011) Trial watch: phase III and submission failures: 2007–2010. Nat Rev Drug Discov 10:87

    Article  PubMed  CAS  Google Scholar 

  • Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687–697

    Article  PubMed  CAS  Google Scholar 

  • Bates SE (2010) Striving to improve outcomes in oncology: unmet expectations in a complex disease. Clin Cancer Res 16:5950

    Article  PubMed  Google Scholar 

  • Beerenwinkel N, Antal T, Dingli D, Traulsen A, Kinzler KW, Velculescu VE, Vogelstein B, Nowak MA (2007) Genetic progression and the waiting time to cancer. PLoS Comput Biol 3:e225

    Article  PubMed  Google Scholar 

  • Buchler P, Reber HA, Eibl G, Roth MA, Buchler MW, Friess H, Isacoff WH, Hines OJ (2005) Combination therapy for advanced pancreatic cancer using Herceptin plus chemotherapy. Int J Oncol 27:1125–1130

    PubMed  Google Scholar 

  • Burch PA, Ghosh C, Schroeder G, Allmer C, Woodhouse CL, Goldberg RM, Addo F, Bernath AM, Tschetter LK, Windschitl HE, Cobau CD (2000) Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial. Am J Clin Oncol 23:534–537

    PubMed  CAS  Google Scholar 

  • Burris HA 3rd, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, Von Hoff DD (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403–2413

    PubMed  CAS  Google Scholar 

  • Byrski T, Huzarski T, Dent R, Gronwald J, Zuziak D, Cybulski C, Kladny J, Gorski B, Lubinski J, Narod S (2009) Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat 115:359–363

    Article  PubMed  CAS  Google Scholar 

  • Cagle PT, Allen TC, Dacic S, Beasley MB, Borczuk AC, Chirieac LR, Laucirica R, Ro JY, Kerr KM (2011) Revolution in lung cancer: new challenges for the surgical pathologist. Arch Pathol Lab Med 135:110–116

    PubMed  Google Scholar 

  • Caponigro G, Sellers WR (2011) Advances in the preclinical testing of cancer therapeutic hypotheses. Nat Rev Drug Discov 10:179–187

    Article  PubMed  CAS  Google Scholar 

  • Chin L, Gray JW (2008) Translating insights from the cancer genome into clinical practice. Nature 452:553–563

    Article  PubMed  CAS  Google Scholar 

  • Chin L, Andersen JN, Futreal PA (2011) Cancer genomics: from discovery science to personalized medicine. Nat Med 17:297–303

    Article  PubMed  CAS  Google Scholar 

  • Clark-Knowles KV, O’Brien AM, Weberpals JI (2010) BRCA1 as a therapeutic target in sporadic epithelial ovarian cancer. J Oncol 2010:891059

  • Cordon-Cardo C (2004) p53 and RB: simple interesting correlates or tumor markers of critical predictive nature? J Clin Oncol 22:975–977

    Article  PubMed  CAS  Google Scholar 

  • Croce CM (2008) Oncogenes and cancer. N Engl J Med 358:502–511

    Article  PubMed  CAS  Google Scholar 

  • da Cunha Santos G, Dhani N, Tu D, Chin K, Ludkovski O, Kamel-Reid S, Squire J, Parulekar W, Moore MJ, Tsao MS (2010) Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer: National Cancer Institute of Canada Clinical Trials Group Study PA.3. Cancer 116:5599–5607

    Article  PubMed  Google Scholar 

  • Doroshow JH (2010) Selecting systemic cancer therapy one patient at a time: is there a role for molecular profiling of individual patients with advanced solid tumors? J Clin Oncol 28:4869–4871

    Article  PubMed  Google Scholar 

  • EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687–1717

    Article  Google Scholar 

  • Editorial (2010) Trial watch: adaptive BATTLE trial uses biomarkers to guide lung cancer treatment. Nat Rev Drug Discov 9:423

  • Esteva FJ, Yu D, Hung MC, Hortobagyi GN (2010) Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat Rev Clin Oncol 7:98–107

    Article  PubMed  CAS  Google Scholar 

  • Farrell A (2011) A close look at cancer. Nat Med 17:262–265

    Article  PubMed  CAS  Google Scholar 

  • Freidlin B, McShane LM, Korn EL (2010) Randomized clinical trials with biomarkers: design issues. J Natl Cancer Inst 102:152–160

    Article  PubMed  CAS  Google Scholar 

  • Gerber DE, Minna JD (2010) ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 18:548–551

    Article  PubMed  CAS  Google Scholar 

  • Green ED, Guyer MS (2011) Charting a course for genomic medicine from base pairs to bedside. Nature 470:204–213

    Article  PubMed  CAS  Google Scholar 

  • Gruver AM, Portier BP, Tubbs RR (2011) Molecular pathology of breast cancer: the journey from traditional practice toward embracing the complexity of a molecular classification. Arch Pathol Lab Med 135:544–557

    PubMed  CAS  Google Scholar 

  • Hall J, Dennler P, Haller S, Pratsinis A, Sauberli K, Towbin H, Walthe K, Woytschak J (2010) Genomics drugs in clinical trials. Nat Rev Drug Discov 9:988

    Article  PubMed  CAS  Google Scholar 

  • Harries M, Smith I (2002) The development and clinical use of trastuzumab (Herceptin). Endocr Relat Cancer 9:75–85

    Article  PubMed  CAS  Google Scholar 

  • Harris T (2010) Gene and drug matrix for personalized cancer therapy. Nat Rev Drug Discov 9:660

    Article  PubMed  Google Scholar 

  • Hood L, Friend SH (2011) Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol 8:184–187

    Article  PubMed  Google Scholar 

  • Hutchinson L (2011) Personalized cancer medicine: era of promise and progress. Nat Rev Clin Oncol 8:121

    Article  PubMed  Google Scholar 

  • ICGC (2010) International network of cancer genome projects. Nature 464:993–998

    Article  Google Scholar 

  • Isacoff WH, Bendetti JK, Barstis JJ, Jazieh AR, Macdonald JS, Philip PA (2007) Phase II trial of infusional fluorouracil, leucovorin, mitomycin, and dipyridamole in locally advanced unresectable pancreatic adenocarcinoma: SWOG S9700. J Clin Oncol 25:1665–1669

    Article  PubMed  CAS  Google Scholar 

  • Jimeno A, Tan AC, Coffa J, Rajeshkumar NV, Kulesza P, Rubio-Viqueira B, Wheelhouse J, Diosdado B, Messersmith WA, Iacobuzio-Donahue C, Maitra A, Varella-Garcia M, Hirsch FR, Meijer GA, Hidalgo M (2008) Coordinated epidermal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer. Cancer Res 68:2841–2849

    Article  PubMed  CAS  Google Scholar 

  • Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968–972

    Article  PubMed  CAS  Google Scholar 

  • Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801–1806

    Article  PubMed  CAS  Google Scholar 

  • Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757–1765

    Article  PubMed  CAS  Google Scholar 

  • Khleif SN, Doroshow JH, Hait WN (2010) AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 16:3299–3318

    Article  PubMed  CAS  Google Scholar 

  • Kim ES, Herbst1 RS et al. (2011) The BATTLE Trial: personalizing therapy for lung cancer. Cancer Discov 1

  • Kimura K, Sawada T, Komatsu M, Inoue M, Muguruma K, Nishihara T, Yamashita Y, Yamada N, Ohira M, Hirakawa K (2006) Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine. Clin Cancer Res 12:4925–4932

    Article  PubMed  CAS  Google Scholar 

  • Kovacs A, Stenman G (2010) HER2-testing in 538 consecutive breast cancer cases using FISH and immunohistochemistry. Pathol Res Pract 206:39–42

    Article  PubMed  Google Scholar 

  • Lee CK, Lord SJ, Coates AS, Simes RJ (2009) Molecular biomarkers to individualise treatment: assessing the evidence. Med J Aust 190:631–636

    PubMed  Google Scholar 

  • Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22:735–742

    Article  PubMed  CAS  Google Scholar 

  • Link DC, Schuettpelz LG, Shen D, Wang J, Walter MJ, Kulkarni S, Payton JE, Ivanovich J, Goodfellow PJ, Le Beau M, Koboldt DC, Dooling DJ, Fulton RS, Bender RH, Fulton LL, Delehaunty KD, Fronick CC, Appelbaum EL, Schmidt H, Abbott R, O’Laughlin M, Chen K, McLellan MD, Varghese N, Nagarajan R, Heath S, Graubert TA, Ding L, Ley TJ, Zambetti GP, Wilson RK, Mardis ER (2011) Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA 305:1568–1576

    Article  PubMed  CAS  Google Scholar 

  • LoRusso PM, Schnipper LE, Stewart DJ, Boerner SA, Averbuch SD, Wolf W (2010) Translating clinical trials into meaningful outcomes. Clin Cancer Res 16:5951–5955

    Article  PubMed  Google Scholar 

  • Macconaill LE, Garraway LA (2010) Clinical implications of the cancer genome. J Clin Oncol 28:5219–5228

    Article  PubMed  Google Scholar 

  • MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, Niu L, Davis M, Yao K, Hanna M, Mondal C, Luongo L, Emery CM, Baker AC, Philips J, Goff DJ, Fiorentino M, Rubin MA, Polyak K, Chan J, Wang Y, Fletcher JA, Santagata S, Corso G, Roviello F, Shivdasani R, Kieran MW, Ligon KL, Stiles CD, Hahn WC, Meyerson ML, Garraway LA (2009) Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4:e7887

    Article  PubMed  Google Scholar 

  • Majewski IJ, Bernards R (2011) Taming the dragon: genomic biomarkers to individualize the treatment of cancer. Nat Med 17:304–312

    Article  PubMed  CAS  Google Scholar 

  • Mandrekar SJ, Sargent DJ (2009) Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. J Clin Oncol 27:4027–4034

    Article  PubMed  Google Scholar 

  • McClellan M, Benner J, Schilsky R, Epstein D, Woosley R, Friend S, Sidransky D, Geoghegan C, Kessler D (2011) An accelerated pathway for targeted cancer therapies. Nat Rev Drug Discov 10:79–80

    Article  PubMed  CAS  Google Scholar 

  • McDermott U, Downing JR, Stratton MR (2011) Genomics and the continuum of cancer care. N Engl J Med 364:340–350

    Article  PubMed  CAS  Google Scholar 

  • Mellinghoff IK, Sawyers CL (2002) The emergence of resistance to targeted cancer therapeutics. Pharmacogenomics 3:603–623

    Article  PubMed  CAS  Google Scholar 

  • Mendelsohn J, Tursz T, Schilsky RL, Lazar V (2011) WIN Consortium-challenges and advances. Nat Rev Clin Oncol 8:133–134

    Article  PubMed  Google Scholar 

  • Michalski CW, Weitz J, Buchler MW (2007) Surgery insight: surgical management of pancreatic cancer. Nat Clin Pract Oncol 4:526–535

    Article  PubMed  Google Scholar 

  • Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960–1966

    Article  PubMed  CAS  Google Scholar 

  • Nathanson KL (2010) Using genetics and genomics strategies to personalize therapy for cancer: focus on melanoma. Biochem Pharmacol 80:755–761

    Article  PubMed  CAS  Google Scholar 

  • Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973–977

    Article  PubMed  CAS  Google Scholar 

  • Nelson NJ (2010) Adaptive clinical trial design: has its time come? J Natl Cancer Inst 102:1217–1218

    Article  PubMed  Google Scholar 

  • Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358:1576–1585

    Article  PubMed  CAS  Google Scholar 

  • Ocana A, Tannock IF (2011) When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst 103:16–20

    Article  PubMed  Google Scholar 

  • Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267–277

    Article  PubMed  CAS  Google Scholar 

  • Pajic M, Scarlett CJ, Chang DK, Sutherland RL, Biankin AV (2011) Preclinical strategies to define predictive biomarkers for therapeutically relevant cancer subtypes. Hum Genet. doi:10.1007/s00439-011-0990-0

  • Palanisamy N, Ateeq B, Kalyana-Sundaram S, Pflueger D, Ramnarayanan K, Shankar S, Han B, Cao Q, Cao X, Suleman K, Kumar-Sinha C, Dhanasekaran SM, Chen YB, Esgueva R, Banerjee S, LaFargue CJ, Siddiqui J, Demichelis F, Moeller P, Bismar TA, Kuefer R, Fullen DR, Johnson TM, Greenson JK, Giordano TJ, Tan P, Tomlins SA, Varambally S, Rubin MA, Maher CA, Chinnaiyan AM (2010) Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 16:793–798

    Article  PubMed  CAS  Google Scholar 

  • Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–1812

    Article  PubMed  CAS  Google Scholar 

  • Philip PA, Mooney M, Jaffe D, Eckhardt G, Moore M, Meropol N, Emens L, O’Reilly E, Korc M, Ellis L, Benedetti J, Rothenberg M, Willett C, Tempero M, Lowy A, Abbruzzese J, Simeone D, Hingorani S, Berlin J, Tepper J (2009) Consensus report of the national cancer institute clinical trials planning meeting on pancreas cancer treatment. J Clin Oncol 27:5660–5669

    Article  PubMed  Google Scholar 

  • Polyak K, Garber J (2011) Targeting the missing links for cancer therapy. Nat Med 17:283–284

    Article  PubMed  CAS  Google Scholar 

  • Rodríguez-Paredes M, Esteller M (2011) Cancer epigenetics reaches mainstream oncology. Nat Med 17:330–339

    Article  PubMed  Google Scholar 

  • Rosenberger WF, Lachin JM (1993) The use of response-adaptive designs in clinical trials. Control Clin Trials 14:471–484

    Article  PubMed  CAS  Google Scholar 

  • Safran H, Iannitti D, Ramanathan R, Schwartz JD, Steinhoff M, Nauman C, Hesketh P, Rathore R, Wolff R, Tantravahi U, Hughes TM, Maia C, Pasquariello T, Goldstein L, King T, Tsai JY, Kennedy T (2004) Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Cancer Invest 22:706–712

    Article  PubMed  CAS  Google Scholar 

  • Sargent DJ, Conley BA, Allegra C, Collette L (2005) Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 23:2020–2027

    Article  PubMed  Google Scholar 

  • Schilsky RL (2010) Personalized medicine in oncology: the future is now. Nat Rev Drug Discov 9:363–366

    Article  PubMed  CAS  Google Scholar 

  • Seruga B, Hertz PC, Wang L, Booth CM, Cescon DW, Krzyzanowska M, Tannock IF (2010) Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. Ann Oncol 21:1411–1418

    Article  PubMed  CAS  Google Scholar 

  • Shekhar MP (2011) Drug resistance: challenges to effective therapy. Curr Cancer Drug Targets 11:613–623

    Google Scholar 

  • Showalter SL, Charles S, Belin J, Cozzitorto J, Einstein P, Richards NG, Sauter PK, Kennedy EP, Witkiewicz A, Brody JR, Yeo CJ (2010) Identifying pancreatic cancer patients for targeted treatment: the challenges and limitations of the current selection process and vision for the future. Expert Opin Drug Deliv 7:273–284

    Article  PubMed  CAS  Google Scholar 

  • Solit DB, Rosen N (2011) Resistance to BRAF inhibition in melanomas. N Engl J Med 364:772–774

    Article  PubMed  CAS  Google Scholar 

  • Stratton MR, Campbell PJ, Futreal PA (2009) The cancer genome. Nature 458:719–724

    Article  PubMed  CAS  Google Scholar 

  • Tabernero J, Macarulla T (2009) Changing the paradigm in conducting randomized clinical studies in advanced pancreatic cancer: an opportunity for better clinical development. J Clin Oncol 27:5487–5491

    Article  PubMed  Google Scholar 

  • TCGA CGARN (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068

    Google Scholar 

  • TCGA (2008b) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455:1061–1068

    Article  Google Scholar 

  • Tursz T, Andre F, Lazar V, Lacroix L, Soria JC (2011) Implications of personalized medicine-perspective from a cancer center. Nat Rev Clin Oncol 8:177–183

    Article  PubMed  Google Scholar 

  • van der Heijden MS, Brody JR, Gallmeier E, Cunningham SC, Dezentje DA, Shen D, Hruban RH, Kern SE (2004) Functional defects in the Fanconi anemia pathway in pancreatic cancer cells. Am J Pathol 165:651–657

    Article  PubMed  Google Scholar 

  • van der Heijden MS, Brody JR, Dezentje DA, Gallmeier E, Cunningham SC, Swartz MJ, DeMarzo AM, Offerhaus GJ, Isacoff WH, Hruban RH, Kern SE (2005) In vivo therapeutic responses contingent on Fanconi anemia/BRCA2 status of the tumor. Clin Cancer Res 11:7508–7515

    Article  PubMed  Google Scholar 

  • Villarroel MC, Rajeshkumar NV, Garrido-Laguna I, De Jesus-Acosta A, Jones S, Maitra A, Hruban RH, Eshleman JR, Klein A, Laheru D, Donehower R, Hidalgo M (2011) Personalizing cancer treatment in the age of global genomic analyses: PALB2 gene mutations and the response to DNA damaging agents in pancreatic cancer. Mol Cancer Ther 10:3–8

    Article  PubMed  CAS  Google Scholar 

  • Von Hoff DD, Stephenson JJ Jr, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, Fitch TR, Wasserman E, Fernandez C, Green S, Sutherland W, Bittner M, Alarcon A, Mallery D, Penny R (2010) Pilot study using molecular profiling of patients’ tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 28:4877–4883

    Article  Google Scholar 

  • Wheeler DL, Dunn EF, Harari PM (2010) Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol 7:493–507

    Article  PubMed  CAS  Google Scholar 

  • Wistuba II, Gelovani JG, Jacoby JJ, Davis SE, Herbst RS (2011) Methodological and practical challenges for personalized cancer therapies. Nat Rev Clin Oncol 8:135–141

    Article  PubMed  CAS  Google Scholar 

  • Xia B, Dorsman JC, Ameziane N, de Vries Y, Rooimans MA, Sheng Q, Pals G, Errami A, Gluckman E, Llera J, Wang W, Livingston DM, Joenje H, de Winter JP (2007) Fanconi anemia is associated with a defect in the BRCA2 partner PALB2. Nat Genet 39:159–161

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Research Program, Garvan Institute of Medical Research, 384 Victoria St, Darlinghurst, Sydney, NSW, 2010, Australia

    Andrew V. Biankin

  2. Ontario Institute for Cancer Research, 101 College Street, Toronto, ON, M5G 0A3, Canada

    Thomas J. Hudson

Authors
  1. Andrew V. Biankin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas J. Hudson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Thomas J. Hudson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Biankin, A.V., Hudson, T.J. Somatic variation and cancer: therapies lost in the mix. Hum Genet 130, 79–91 (2011). https://doi.org/10.1007/s00439-011-1010-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00439-011-1010-0

Keywords

Search

Navigation